blinatumomab
amgen,astellas
['leukemia', 'blinatumomab']
mark litzow presents results from a phase 3 blinatumomab for mrd negative all patients. primary endpoint of os was significant. ae data not shown. #ash22 
The Lancet Haematology is a world-leading #haematology journal publishing peer-reviewed research and reviews, opinion, and news. #hematology